• This record comes from PubMed

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis

. 2017 Jan ; 23 (1) : 51-61. [epub] 20160711

Language English Country England, Great Britain Media print-electronic

Document type Journal Article, Research Support, Non-U.S. Gov't

BACKGROUND: Disease progression and treatment efficacy vary among individuals with multiple sclerosis. Reliable predictors of individual disease outcomes are lacking. OBJECTIVE: To examine the accuracy of the early prediction of 12-year disability outcomes using clinical and magnetic resonance imaging (MRI) parameters. METHODS: A total of 177 patients from the original Avonex-Steroids-Azathioprine study were included. Participants underwent 3-month clinical follow-ups. Cox models were used to model the associations between clinical and MRI markers at baseline or after 12 months with sustained disability progression (SDP) over the 12-year observation period. RESULTS: At baseline, T2 lesion number, T1 and T2 lesion volumes, corpus callosum (CC), and thalamic fraction were the best predictors of SDP (hazard ratio (HR) = 1.7-4.6; p ⩽ 0.001-0.012). At 12 months, Expanded Disability Status Scale (EDSS) and its change, number of new or enlarging T2 lesions, and CC volume % change were the best predictors of SDP over the follow-up (HR = 1.7-3.5; p ⩽ 0.001-0.017). A composite score was generated from a subset of the best predictors of SDP. Scores of ⩾4 had greater specificity (90%-100%) and were associated with greater cumulative risk of SDP (HR = 3.2-21.6; p < 0.001) compared to the individual predictors. CONCLUSION: The combination of established MRI and clinical indices with MRI volumetric predictors improves the prediction of SDP over long-term follow-up and may provide valuable information for therapeutic decisions.

References provided by Crossref.org

Newest 20 citations...

See more in
Medvik | PubMed

Relationship between brain atrophy and disability in a multi-site multiple sclerosis registry

. 2025 ; 7 (2) : e001126. [epub] 20250722

Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide

. 2022 ; 13 () : 991291. [epub] 20220927

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease

. 2020 ; 13 () : 1756286420975223. [epub] 20201207

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS

. 2019 Mar ; 40 (3) : 446-452. [epub] 20190228

Cognitive clinico-radiological paradox in early stages of multiple sclerosis

. 2018 Jan ; 5 (1) : 81-91. [epub] 20171215

The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials

. 2016 ; 11 (9) : e0163296. [epub] 20160929

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...